← All trials

NCT04715646

Phase 3Interventional

Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.

View on ClinicalTrials.gov ↗

Timeline

Start date
Mar 11, 2021
Primary completion
Apr 30, 2025
Completion date
Apr 30, 2025
First posted
Jan 20, 2021
Last posted
Nov 10, 2021
Enrollment
100
Arms / groups
1 / —
Source
AACT · ingestion pipeline

Sponsors

  • UCBLead sponsor
  • UCBStudy director

Drugs studied

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.